The series B gives Bigfoot the financial muscle to move its automated insulin infusion device into a pivotal clinical trial in the U.S. next year. 

The technology is designed to support the performance and interpretation of echocardiograms.

Grail will start next year led by a CEO with 30 years of biopharma experience, having been run by a former Google executive until August.

Brainsway will put the money into the commercialization of its transcranial stimulation product and the expansion of its use into new indications.

The product is a small titanium device that is implanted beneath the skin to provide access to an arteriovenous fistula.

Rather than limit its criteria to financial returns, LSP also looks at the effect each company will have on healthcare quality and economics.

The round equips the drug delivery device specialist move its transdermal ibuprofen patch candidate into the clinic early next year.

Apprentice has raised money to build out its biopharma-focused augmented reality business.